Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree, great news for longs that a highly successful and enormous family fund is putting their money into nwbo!
have a great one pal! by.
Because that is NORMAL. Not exactly sure what “dilution” to which you refer, but all dilution is necessary to be commercially viable and not go bankrupt at the pre-revenue stage. No shareholder is in a position to manage the company from a billion miles high. That’s why we have people who actually manage companies and make such decisions.
I have an example just the other day of how reasonable it would be if the company got only 15,000 patients for GBM alone in the markets it is in only currently, and how that could easily generate a substantial price per share with 1.5 billions shares outstanding. If it extends the indications beyond GBM to new and recurrent cancers in various indications, and assuming the Flaskworks scaling works in terms of manufacturing, which I have no reason to not expect, in a few years it certainly could reach a very substantial market cap, engage in share buybacks and reach a substantial per share value.
Plus you can have irrational enthusiasm as we see with Tesla.
Nonsense. It is 2022. Not 2011. We now have a completed trial, nearly certified commercial manufacturing, an approved PIP and approvable data per the experts.
have a good one pal. by.
That should read up almost 60% per year for 5 years, not up 60% total, I was quoting the comment made to me about what I had said previously, to respond, but the reply mischaracterized what I had said in numerous instances.
Nope.
A huge difference between the science and the regulatory side of the issue.
I see nothing in LP';s bio that says she is any sort of an expert on the latter.
at least you’re on record now explicitly stating you think you know the science better than Linda Liau. This presentation is not by NWBO, but a prominent scientist—an important difference.
PM, I fear either you’re going through a ramen overdose reaction or I’m enjoying my daily red wine too much
You are obviously an intelligent person who has made it to the finest of the park bench neighborhood, and taking a profit of any size is better than a loss. So you do you and I respect you in any event.
As for me, I’m a sucker for a perceived bargain and a perma optimist, and although I have struck out several times before with bases loaded and two outs with the winning run being me at bat, I still like the opportunity of swinging for the fences!!!
This time we might be in the 18th inning but our team has managed to put three men on base and the pitcher is tired, and our home team is energized and awaiting the 3-2 pitch!
It’s at that moment I woke up
Checkmating after a highly successful P3 trial is an impossible task.
That, plus at this time there's not many other hideouts in the market. I think it will be another 3-4 weeks before we see a positive market shift. Hopefully be then we will have some news and maybe a small upward movement so people who have not yet de-risked their investment can get some of their cash out and have better overall market conditions to re-invest the money.
I’m in over 12 years, probably 13 or 14 by now.
The evolving timelines and minimal communication, at least since 2015, have required a lot of patience and faith, however all recent indications are that we are in the final stretch that will provide greater visibility and ultimate approvals of DCVax-L for GBM.
Especially knowing that the phase 3 trial primary and secondary endpoints have been met with ample statistical significance, and that follow on combination trials are indicating promising efficacy and outstanding OS outcomes for an unheard of percentage of combo treatment recipients!!!
I made my decision to stick it out to the end many years ago and to go big or go home. I weigh all the due diligence constantly and my logic keeps coming back as favorable, understanding that nothing is guaranteed and life is full of extremely questionable decisions that somehow get made despite the evidence.
All imho
They have been doing this for years.
The insiders at NVCR obviously know their company is over valued. No secret there. But NWBO’s lack of progress is not only offering them a longer runway to sell and capitalize at a higher share price, but also for insiders to receive additional bonus options, and I assume get past the vesting periods.
NVCR and their investors have made huge money with not much to show for it in terms of what they offer patients. I would say insiders at NVCR are laughing in the back of their limos on their long weekend drives to their homes in the Hamptons or the Vineyard — while I whistle my happy tunes on my park bench.
Weekly Chart Update:
RSI continues to ride the Support Trend Line from Dec. As long as this holds, hard to get overly bearish. Circled the very thin weak part of the cloud upcoming in Nov. That's when I'm also predicting 50/200 Daily Golden Cross to happen. Bottom Long Term MACD Histogram 65,90,12 showing inside 20 EMA and Nice Trend of Higher Lows.
What does a gas guy who created an industry know about investing in a company creating an industry? Answer: A TON.
Hi Ex, I hope you can answer some of these questions, probably not the first one for obvious reasons.
How many dollars is the Crown Short $NWBO?
If the Crown was too short NWBO, who bears the burden of the debt? The taxpayer I assume, but what form would that take?
If a country was so short NWBO that they couldn't print away the problem, what decision would they make?
1) Try to talk down the buyout price?
2) Last minute hedge with a Coronetvirus?
3) Send me in to war? I'd be shooting at the Chinese but I'm long this stock with them. (highly likely)
4) Use citizen's assets as collateral because the taxpayer bears the burden of the debt?
The Prince of Wales' Coronet
Does Canada have a conscientious objector status? How can I be actively betting against my own Country and then be called a deserter and thrown in jail for refusing to fight? They would be saying, "we are not honouring the bet we have against you and we want you to fight for our bank account." That's gross after holding for years.
If you are actively betting against your own country because they took the opposite side, you should be able to consider yourself sovereign without becoming a citizen of another country. At that point why can't I renounce my citizenship? This is currently slavery. Canada's current laws require you to become a citizen of another country prior to renouncing, I assume so that they can deport you.
Why would Canada allow me to become a citizen of an Enemy country and leave freely? One day I may fight against Canada. Why would they not retain the worker in their country? He may not pay tax anymore, but he still contributes to the velocity of money and is productive.
So, is Canada stupid then? I have to be a citizen so that I pay taxes, so that I'm targeted by the Canada Pension Plan Investment Board, but I can become a member of the enemy team? I guess they leave that option open so it doesn't sound so bad.
If national strategies begin with citizens being exploited slaves, where does it end? You don't have to answer this one, the answer is that it doesn't end.
If White was doing good and black was doing bad, all we can do is make black moves.
"The system is broken, the world is in crisis, and things are about to get a lot worse, unless we change." - Justin Trudeau
Where is the Annual Shareholder Meeting?
Delaware virtual meetings are ass and allow a few tech companies to create infinite shell companies that you can't even sue (AI run companies). As soon as you catch on, they close up shop and move on to the next one.
Combine that with Swiss bank accounts and we have an entire SEC that look like scammers. That's America's way to scam us and say we don't know what's going on.
True Somewhere:
To sum up, they took my parent's taxes and shorted my success only to lose and send me in to shoot my real team and if I don't go I'm a deserter in jail. The Windsor PD really likes to say that they just follow protocol and the rules, HOW DO THE RULES SOUND NOW?
HOW CAN WE ONLY PLAY FROM THE DEVIL'S BLACK BOOK AND SING ABOUT GOD? Just another strat to throw you off track.
I think I'd rather talk about Goo-G Heapfind and the Soleilmana in my signature.
Maybe I really did end up on Earth 2 because I was sucked to hell :)
The bots could never come because they were too scared of their skill level :)
They are laughing all the way to the bank where they are collecting money for their shares before they lose more value.
a) that was awesome - thank you
b) hope you will continue to update as we move along the timeline
regards
Na, the insiders at NVCR are selling. The share price continues to spiral. All the while, NWBO remains flat YTD.
Not only are insiders selling but BMY is also cutting and running!
https://clinicaltrials.gov/ct2/show/NCT03430791?cond=glioblastoma+++Opdivo&draw=2&rank=5
NVCR is hurting.
Dr. Musella and the MHRA believe the ECA arm was done correctly. I'd like to see the resume of anyone that disagrees.
The Management of small biotech Company's is very different than running a front-running technology company. The big difference is: You have the one of the largest regulatory bodies in the US Government (FDA) making the decision whether you can market and sell your product or not. You also have many more frivolous lawsuits filed in the biotech field than anywhere else on WS. Both of these "road-blocks" require Management to be much more tight-lipped about anything they may talk about and/or release in a PR. Its the nature of the beast and isnt confined to just NW Bio. Just about every other pre-revenue biotech company I have owned have act very similar. This isn't exclusive to NW Bio. There are wolves at every corner in the biotech space.
Not expecting that either, but would be nice.
I’m sure the guys at NVCR are laughing their rear-ends off right about now, watching this clown show.
You exploit SEC filings to manufacture disinformation. Without its full context, any isolated SEC disclosure is a gross distortion of reality and is misleading. SEC filings are reliable, but they are SEC filings.
Research what these documents are and what their purpose is. Compare the SEC filings for other pre-commercial biotech companies and for well-established commercial companies. By comparison, in context, and with an informed perspective, you can understand their content and their actual significance.
Who on Earth has any guarantees of future events or full control over the choices and decisions of others? Is there any valuable company with zero risk? Apple? Tesla? Amazon? Pfizer? Even the best and the biggest have risks to report. NWBO is not yet commercial, yet you expect it to have fewer risks than a commercial giant?
SEC filings are solid sources. To ensure a proper and accurate understanding of their meaning, they must be read in full and in context. Furthermore, the publication date must be considered for perspective in light of subsequent developments and relevant new circumstances.
https://www.sec.gov/edgar/browse/?CIK=0001072379
https://www.merck.com/investor-relations/financial-information/sec-filings/
We would be lucky if we get a pump this year. It will likely be next year when we are close to UK approvals. We will likely get slammed in the near term due to dilution and overall market dynamics. I’d be happy if we move in the positive direction though.
Imagine November ... will be un-"bearable"
Imagine November ... will be un-"bearable"
Another weekend for bears to spend here… strange behavior
Bullshit narrative. The company isn't promoting anything. This is a letter put put by Hefner. His family fund has probably been invested in NWBO for years and he has released 2 letters. Nothing concerns me about this. This is normal. In fact, just the opposite is true, this is extremely encouraging to see a family that has this much confidence in their investment. It gives me more confidence in my own investment.
Have a great one PM.
:)
If expectations of SNO lead to a $2 over bought share price, then that’s my exit.
In the years that I’ve invested in this stock, nothing has spooked me more than the latest promotion of R. Hefner. And it has nothing to do with him personally, as he’s someone with an accomplished career in the energy sector.
What spooks me is the company should be well past the staged of promoting an angel investor that they seem to be trying to sweet talk into putting in some money. The angel investor days should be over. And aside, if Hefner is so convinced of what NWBO has to offer in terms of DCVax, what is he waiting for!? He’s 87 years old!
No one is pumping SNO. As. shareholder I'm excited to see the world renowned Dr. Liau speak once again about the successful DCVax-L trial.
Have a great one Bobby!
- TS
great info as always. thanks sky.
Wait for the SNO pump to sell. Buy back post SNO when expectations are crushed.
We aren’t so desperate that we have ceased the social media operations. If our favorite consultants disappear then it might be time to dump because things have become dire
ex, curious how you stick to your guns that the trial failed (your reiteration of “but placebo vs ITT!”) when Dr Linda Liau’s SNO presentation is titled:
“DCVax improves survival in newly diagnosed and recurrent GBM: survival results from a phase 3 trial”
Is she in on the scam, and lying? Why would she, or better yet how could she present with this title if your narrative is correct?
Furthermore, for everyone, just imagine if we saw this abstract title a year ago, lol, everyone would be hooting and hollering. But for some reason—the short takedown in May? the current share price?—folks now see this title and just say “yeah we’ll see.”
Consider companies such as Merck, Pfizer, and Bristol Meyers Squibb. They develop medical products involving scientists and doctors. There is also a business and finance side that funds research, development, manufacturing, and acquisitions. Some people work on the science while others are experts on the business side.
Billionaire Robert Hefner is also on the business side of the DCVax platform technology as an investor. He is billionaire expert on other technologies of global value. Hefner is old and has been researchable for many years. He is business expert whom we can vet. We can scrutinize his judgment and his global work over many decades. We can verify his net worth and professional resume to decide whether his opinion about the DCVax platform technology is a significant and valuable opinion.
Everyone should do their own thorough research of trustworthy sources and not accept anonymous disinformation as true. An independent medical peer review is forthcoming. There are also published sources available now such as those pasted below and many others which anyone can find and evaluate for themselves.
https://soc-neuro-onc.org/
https://www.uclahealth.org/providers/linda-liau
https://connect.uclahealth.org/2022/09/14/brain-cancer-discovery-clinical-trials/
https://www.kcl.ac.uk/people/keyoumars-ashkan
https://www.liverpool.ac.uk/systems-molecular-and-integrative-biology/staff/michael-jenkinson/
https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter
https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/
https://virtualtrials.org/dcvax.cfm
https://www.annalsofoncology.org/article/S0923-7534(22)00006-0/fulltext
good example fireman. thanks for sharing.
LOLOLOLOL.
Another bullshit sale deadline. I've seen this before!
bullshit narrative. Didn't read past the first sentence. This is not tsla or nvda. this is a pre revenue biotechnology following a best practice quiet period
Exactly. From the beginning that is what I thought they would do wothbc shares - dilute just enough to keep the lights on.
I picked November to begin taking down my position. If nothing happens from now until then, not sure I can stomach them that much longer.
Nice, I have been in NVDIA and TSLA for a very long time as well. The management there didn’t have a history of BSing like what we have. They didn’t get delisted from a major exchange. They stayed compliant throughout their struggles and didn’t blame shorts and played victim card when they were struggling. They didn’t shy away from communicating with the investors and street about their vision. In our case, it almost appears that they are hiding something by staying in this so called quiet period (2 years since data lock) and not going all out to convince investors and street.
And you know as well as I do that techs and biotechs are very different. Biotech are regulated and hence the valuations don’t fly as high and as quickly as techs. You have got to run trials, convince regulatory authorities, work on reimbursement with various governments, etc.
what does a gas guy know about cancer ???? LOL LOL
Why dilute when you are so close to major catalysts except to keep the lights on?
Followers
|
1630
|
Posters
|
|
Posts (Today)
|
4
|
Posts (Total)
|
706768
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |